MiNK Therapeutics

Update in progress

INKT (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf iNKT cell therapies to treat cancer and immune-mediated diseases. It is advancing agenT-797 in multiple trials, plus MiNK-215 and MiNK-413 programs, and collaborations with Autonomous Therapeutics, ImmunoScape, and C-Further. Formerly AgenTus Therapeutics, renamed in 2021. Founded 2017, based in New York, NY, and a subsidiary of Agenus Inc.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.16; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.02; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.20; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive